Cerebral infarction following subcutaneous immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy

Steve Vucic, FRACP, PhD Karl Ng, FRACP, PhD Department of Neurology and Neurophysiology, Royal North Shore Hospital, St Leonards, New South Wales, Australia Brisbane Waters Private Hospital, Woy Woy, New South Wales, Australia Neurogenetics Unit, Department of Diagnostic Genomics, PathWest Laboratory Medicine, QE II Medical Centre, Nedlands, Western Australia, Australia Department of Neurology, Westmead Hospital, Westmead, New South Wales, Australia Department of Neurophysiology, Westmead Hospital, Westmead, New South Wales, Australia

[1]  W. Sewell,et al.  Is Dosing of Therapeutic Immunoglobulins Optimal? A Review of a Three-Decade Long Debate in Europe , 2014, Front. Immunol..

[2]  S. Blanton,et al.  A novel mutation in VCP causes Charcot-Marie-Tooth Type 2 disease. , 2014, Brain : a journal of neurology.

[3]  G. Marfia,et al.  Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study , 2014, Journal of Neurology.

[4]  M. Benatar,et al.  Motor neuron involvement in multisystem proteinopathy , 2013, Neurology.

[5]  J. Jakobsen,et al.  Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy , 2013, European journal of neurology.

[6]  H. J. Schelhaas,et al.  Hereditary spastic paraplegia caused by a mutation in the VCP gene. , 2012, Brain : a journal of neurology.

[7]  A. Rae-Grant,et al.  Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders , 2012, Neurology.

[8]  I. Nonaka,et al.  Characterization of the Asian myopathy patients with VCP mutations , 2012, European journal of neurology.

[9]  N. Ertekin-Taner,et al.  Novel p.Ile151Val mutation in VCP in a patient of African American descent with sporadic ALS , 2011, Neurology.

[10]  D. Burke,et al.  Axonal hyperpolarization in inclusion‐body myopathy, paget disease of the bone, and frontotemporal dementia (IBMPFD) , 2011, Muscle & nerve.

[11]  Patrizia Sola,et al.  Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS , 2011, Neuron.

[12]  F. Mastaglia,et al.  Two Australian families with inclusion-body myopathy, Paget’s disease of bone and frontotemporal dementia: Novel clinical and genetic findings , 2010, Neuromuscular Disorders.

[13]  A. Pestronk,et al.  Valosin-containing protein disease: Inclusion body myopathy with Paget’s disease of the bone and fronto-temporal dementia , 2009, Neuromuscular Disorders.

[14]  L. Hobson‐Webb,et al.  Case-control study of thromboembolic events associated with IV immunoglobulin , 2009, Journal of Neurology.

[15]  I. Marie,et al.  Intravenous immunoglobulin‐associated arterial and venous thrombosis; report of a series and review of the literature , 2006, The British journal of dermatology.

[16]  A. Pestronk,et al.  Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein , 2004, Nature Genetics.

[17]  M. Cartwright,et al.  The clinical features of 16 cases of stroke associated with administration of IVIg , 2003, Neurology.